Nepicastat + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorder
Conditions
Posttraumatic Stress Disorder
Trial Timeline
Jul 1, 2009 → Aug 30, 2012
NCT ID
NCT00659230About Nepicastat + Placebo
Nepicastat + Placebo is a phase 2 stage product being developed by Johnson & Johnson for Posttraumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00659230. Target conditions include Posttraumatic Stress Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00659230 | Phase 2 | Completed |
Competing Products
8 competing products in Posttraumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Adjunctive asenapine | Merck | Approved | 85 |
| sertraline (Zoloft) | Pfizer | Pre-clinical | 22 |
| Ziprasidone | Pfizer | Approved | 84 |
| Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg | Brain Biotech | Phase 2 | 44 |
| High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis | Tilray | Phase 2 | 47 |
| Riluzole | Brain Biotech | Phase 1 | 25 |